In this large cohort of 13,559 patients with non-valvular afib in an integrated health care system, researchers determine the net clinical benefit of warfarin. They calculated benefit by the annual risk of CVA/emboli – the annual risk of intracranial hemorrhage (times a 1.5 “impact factor”). They found no net clinical benefit for those with CHADS2 scores of 0-1, but a 2.2% annual benefit for those with CHADS2 scores 4-6. The greatest benefit was found in those with a history of CVA and age >85 (abstract).
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment